Heparan sulfate glycosaminoglycan (HS-GAG)

Heparan sulfate glycosaminoglycans (HS-GAGs) are complex, highly sulfated linear polysaccharides found ubiquitously on cell surfaces and within the extracellular matrix (ECM) as components of proteoglycans (NIH, 2020). They play a fundamental role in physiological processes by acting as co-receptors for various growth factors (e.g., FGF, VEGF), chemokines, and morphogens, thereby regulating cell signaling, proliferation, and adhesion (Wikipedia, 2023; NIH, 2024). In pathological contexts, HS-GAGs are frequently exploited by viruses, such as SARS-CoV-2 and Herpes Simplex Virus, as attachment factors to facilitate host cell entry (NIH, 2022). Furthermore, in cancer, HS-GAGs and their remodeling enzyme, heparanase, are involved in promoting tumor angiogenesis, invasion, and metastasis (MDPI, 2021). Therapeutic strategies targeting HS-GAGs include the use of heparin mimetics to competitively inhibit ligand binding or small molecules to block heparanase activity (Frontiers, 2019). However, because of their structural similarity to the anticoagulant heparin, drugs targeting HS-GAGs must be carefully designed to avoid significant bleeding risks and other off-target effects on systemic homeostasis (NIH, 2023).

Other names

Heparan sulfateHeparan sulphateHeparitin sulfateCell surface heparan sulfateHS-GAG

Drugs targeting heparan sulfate glycosaminoglycans typically act through competitive inhibition of ligand binding (e.g., blocking viral spike proteins or growth factors from attaching to the cell surface), inhibition of the remodeling enzyme heparanase to prevent chain degradation and ligand release, or direct neutralization of the polysaccharide's high negative charge (NIH, 2020; NIH, 2022).